Pricing & Access· June 10, 2026 · 10 min readPD-1/PD-L1 checkpoint inhibitor access landscape in 2026Compare payer coverage, HCPCS codes, SC formulations, step therapy, IRA Part B negotiation, and biosimilar horizon across Keytruda,...By Ran Chen#PD-1#PD-L1#Oncology
Approvals· June 7, 2026 · 8 min readImfinzi + BCG for NMIBC access guide: FDA approval, coding, and buy-and-billImfinzi plus BCG was approved May 28, 2026 for BCG-naïve high-risk NMIBC — the first immunotherapy combo in this setting. Maps coding,...By Ran Chen#Oncology#PD-L1#Prior Authorization
Pricing & Access· May 29, 2026 · 10 min readTecentriq Hybreza bladder cancer MRD access guideAccess guide for Tecentriq and Tecentriq Hybreza in ctDNA MRD-guided bladder cancer, including Signatera CDx, IV vs SC dosing, coding,...By Ran Chen#Oncology#PD-L1#Companion Diagnostic